Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Literature DB >> 29089725

Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Timothy C Hutcherson, Nicole E Cieri-Hutcherson, Rajvi Bhatt.

Abstract

Idarucizumab is the first reversal agent approved for the direct thrombin inhibitor dabigatran. The authors summarize the findings from the clinical trial series and describe case reports, post-marketing data, and ongoing studies.

Entities: Chemical Gene

Keywords: Pradaxa; Praxbind; anticoagulation; dabigatran; idarucizumab; reversal agent

Year: 2017 PMID： 29089725 PMCID： PMC5642158

Source DB: PubMed Journal: P T ISSN： 1052-1372

57 in total

1. Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update.

Authors: Manuel Cappellari; Stefano Forlivesi; Giovanna Maddalena Squintani; Roberto Facchinetti; Paolo Bovi
Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300

2. Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer.

Authors: G Turine; A Peeters; C Hermans; S Eeckhoudt; T Duprez
Journal: Acta Neurol Belg Date: 2017-01-30 Impact factor: 2.396

3. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.

Authors: Hervé Quintard; Delphine Viard; Milou-Daniel Drici; Caroline Ruetsch; Charles Marc Samama; Carole Ichai
Journal: Thromb Haemost Date: 2016-10-13 Impact factor: 5.249

4. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.

Authors: Anna Tomaszuk-Kazberuk; Paulina Łopatowska; Elżbieta Młodawska; Joanne van Ryn; Paul A Reilly; Charles V Pollack
Journal: Pol Arch Intern Med Date: 2017-01-31

5. Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database.

Authors: Albert Trinh-Duc; Agnès Lillo-Le Louët; Eric Tellier; Thibault Viard; Grégoire Le Gal; David M Smadja
Journal: Thromb Res Date: 2016-08-24 Impact factor: 3.944

6. Idarucizumab for Dabigatran Reversal in Emergency Type-A Aortic Dissection.

Authors: Reney S Henderson; Seema Deshpande; Brittney Williams; Brad S Taylor; Kenichi A Tanaka
Journal: J Cardiothorac Vasc Anesth Date: 2016-05-13 Impact factor: 2.628

7. Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report.

Authors: Roberto Facchinetti; Giulia DeGuidi; Federica Pitoni; Giorgio Ricci; Giuseppe Lippi
Journal: Blood Coagul Fibrinolysis Date: 2017-10 Impact factor: 1.276

8. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.

Authors: Stefan Hofer; Christoph Philipsenburg; Markus A Weigand; Thorsten Brenner
Journal: A A Case Rep Date: 2016-12-01

9. Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report.

Authors: Waldemar Kafke; Peter Kraft
Journal: Case Rep Neurol Date: 2016-06-27

10. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Authors: Stephan Glund; Joachim Stangier; Joanne van Ryn; Michael Schmohl; Viktoria Moschetti; Wouter Haazen; Marina De Smet; Dietmar Gansser; Stephen Norris; Benjamin Lang; Paul Reilly; Jörg Kreuzer
Journal: Clin Pharmacokinet Date: 2017-01 Impact factor: 6.447

3 in total